UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Annals of oncology, 2021-09, Vol.32 (9), p.1148-1156

2021

Volltextzugriff (PDF)

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The New England journal of medicine, 2021-04, Vol.384 (16), p.1529-1541

2021

Volltextzugriff (PDF)

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

Breast cancer research and treatment, 2021-11, Vol.190 (2), p.265-275

2021

Volltextzugriff (PDF)

Breast Conservation Rates and Outcomes in Postmenopausal Women With Estrogen Receptor-positive Breast Cancer Treated With Neoadjuvant Hormonal Therapy or Chemotherapy

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S229-S230

2012

Volltextzugriff (PDF)

Radiotherapy Implications for Locally Advanced Breast Cancer Patients Treated with Skin Sparing vs. Non-skin Sparing Mastectomy following Neoadjuvant Chemotherapy

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S215-S216

2010

Volltextzugriff (PDF)

Treatment Adherence and Outcome in Women with Inflammatory Breast Cancer: Does Race Matter?

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S245-S246

2010

Volltextzugriff (PDF)

ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer

International journal of radiation oncology, biology, physics, 2024-10, Vol.120 (2), p.S164-S164

2024

Volltextzugriff (PDF)

PCN465 VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/ HER2- METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY

Value in health, 2019-11, Vol.22, p.S527

2019

Volltextzugriff (PDF)

Abstract OT3-03-01: MADELINE: A prospective observational study of mobile app-based patient reported outcomes in advanced breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT3-03-01-OT3-03-01

2017

Volltextzugriff (PDF)

Mitotic Kinesin Inhibitors Induce Mitotic Arrest and Cell Death in Taxol-resistant and -sensitive Cancer Cells

The Journal of biological chemistry, 2005-03, Vol.280 (12), p.11569-11577

2005

Volltextzugriff (PDF)

275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)

Annals of oncology, 2020-09, Vol.31, p.S349-S350

2020

Volltextzugriff (PDF)

Abstract P6-16-03: Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-16-03

2017

Volltextzugriff (PDF)

Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT2-01-05-OT2-01-05

2017

Volltextzugriff (PDF)

Abstract PD5-11: Not presented

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.PD5-11-PD5-11

2018

Volltextzugriff (PDF)

Survivin deregulation in β-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to Taxol

Cancer research (Chicago, Ill.), 2004-12, Vol.64 (23), p.8708-8714

2004

Volltextzugriff (PDF)

Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS3-08-GS3-08

2018

Volltextzugriff (PDF)

The Effect of Radiotherapy on Local Regional Recurrence among Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.4114-4114

2009

Volltextzugriff (PDF)

Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.1118-1118

2011

Volltextzugriff (PDF)

High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.625-625

2010

Volltextzugriff (PDF)

Comparison of 21-gene recurrence score (RS) in African-American (AA) and Caucasian (C) patients with hormone receptor (HR)-positive early-stage breast cancer

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.557-557

2010

Volltextzugriff (PDF)

Abstract P2-09-13: 21 Gene Recurrence Scores: Racial Differences in Testing, Scores, Treatment, and Outcome

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P2-P2-09-13

2010

Volltextzugriff (PDF)

FOREWORD: THE PAST, PRESENT, AND FUTURE OF THE FEDERAL TAX LEGISLATIVE PROCESS

Law and contemporary problems, 2018-03, Vol.81 (2), p.1-6

2018

Volltextzugriff (PDF)

A randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for Her2 negative breast cancers

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.5122

2009

Volltextzugriff (PDF)

No "One Size Fits All" Approach Exists

Oncology (Williston Park, N.Y.), 2019-01, Vol.33 (1), p.21

Zelnak, Amelia B

2019

Volltextzugriff (PDF)

1 – 25 von 88

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(77)

Publikationsform

Artikel
(85)
Buchkapitel
(3)

Sprache

Englisch
(88)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Humans
(30)
Oncology
(30)
Female
(27)
Breast Cancer
(20)
Breast Neoplasms - Drug Therapy
(15)
Breast Neoplasms - Pathology
(13)
Middle Aged
(13)
Adult
(11)
Aged
(10)
Hematology, Oncology And Palliative Medicine
(8)
Neoplasm Staging
(7)
Antineoplastic Agents - Therapeutic Use
(6)
Breast Neoplasms - Metabolism
(6)
Cancer
(6)
Chemotherapy
(6)
Neoadjuvant Therapy
(6)
Radiology
(6)
Treatment Outcome
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

Breast Conservation Rates and Outcomes in Postmenopausal Women With Estrogen Receptor-positive Breast Cancer Treated With Neoadjuvant Hormonal Therapy or Chemotherapy

Radiotherapy Implications for Locally Advanced Breast Cancer Patients Treated with Skin Sparing vs. Non-skin Sparing Mastectomy following Neoadjuvant Chemotherapy

Treatment Adherence and Outcome in Women with Inflammatory Breast Cancer: Does Race Matter?

ctDNA Predicts Pain Response in a Multi-Institutional Phase II Trial of Palliative Radiation, Palbociclib and Hormone Therapy in Metastatic Breast Cancer

PCN465 VIRTUAL COMMUNITY ENGAGEMENT AMONG WOMEN RECEIVING PALBOCICLIB FOR HR+/ HER2- METASTATIC BREAST CANCER: DATA FROM THE MADELINE STUDY

Abstract OT3-03-01: MADELINE: A prospective observational study of mobile app-based patient reported outcomes in advanced breast cancer

Mitotic Kinesin Inhibitors Induce Mitotic Arrest and Cell Death in Taxol-resistant and -sensitive Cancer Cells

275O Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)

Abstract P6-16-03: Phase 2 trial of everolimus and/or trastuzumab in hormone refractory, hormone receptor (HR)-positive, HER2-normal metastatic breast cancer (MBC)

Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor

Abstract PD5-11: Not presented

Survivin deregulation in β-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to Taxol

Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

The Effect of Radiotherapy on Local Regional Recurrence among Patients with Pathologic Complete Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers

High pathologic complete response (pCR) in HER2-positive breast cancer to novel nonanthracycline neoadjuvant chemotherapy

Comparison of 21-gene recurrence score (RS) in African-American (AA) and Caucasian (C) patients with hormone receptor (HR)-positive early-stage breast cancer

Abstract P2-09-13: 21 Gene Recurrence Scores: Racial Differences in Testing, Scores, Treatment, and Outcome

FOREWORD: THE PAST, PRESENT, AND FUTURE OF THE FEDERAL TAX LEGISLATIVE PROCESS

A randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for Her2 negative breast cancers

No "One Size Fits All" Approach Exists

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial

Suchergebnisse filtern